Xilio Therapeutics Stock Plunges Following Initial Phase 2 Data for Vilastobart in Colorectal Cancer Treatment

Stock Price Impact:
Xilio Therapeutics' stock price has dropped following the release of initial Phase 2 data for Vilastobart (XTX101), a tumor-activated anti-CTLA-4, in combination with atezolizumab for treating metastatic microsatellite stable colorectal cancer (MSS CRC)3.

Clinical Trial Results:
The Phase 2 data showed a 27% preliminary response rate in heavily pre-treated MSS CRC patients without liver metastases. Responses were accompanied by decreases in carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) levels, and improvement in clinical symptoms3.

Safety Profile:
The data demonstrated a differentiated safety and tolerability profile for the combination, with a low incidence of immune-related adverse events3.

Market Analysis:
Despite the promising clinical data, the stock price has been affected, possibly due to market expectations and the competitive landscape in colorectal cancer treatments.

Price Prediction:
According to CoinCodex, the stock is predicted to rise by 5.79% and reach $1.14248 per share by February 15, 2025, indicating a bullish sentiment despite the current fear index1.

Comparison with Competitors:
Other companies like Adagene are also developing anti-CTLA-4 therapies, such as ADG126, which has shown promising results in combination with pembrolizumab for MSS CRC patients25.

Sources:

1. https://coincodex.com/stock/XLO/price-prediction/

2. https://www.biospace.com/adagene-presents-interim-results-reinforcing-best-in-class-profile-of-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-metastatic-microsatellite-stable-mss-colorectal-cancer-crc

3. https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-phase-2-data-vilastobart

5. https://investor.adagene.com/news-releases/news-release-details/adagene-presents-results-esmo-congress-show-best-class-8